Evidence map›Paper›PMID 27070911›Full record

ReviewInflammatory bowel diseases2016

Current Understanding of Dysbiosis in Disease in Human and Animal Models.

Arianna K DeGruttola, Daren Low, Atsushi Mizoguchi, Emiko Mizoguchi

Registry-linked trialOpen access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Inflammatory bowel diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06408610 (Moderate Continuous Versus High Interval Intensity Training on Gut Dysbiosis and Glucagon Like Peptide Hormone in Irritable Bowel Syndrome), which is not on this map. Cited by 645 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
645citing papers in PubMed, 7 pooled it
24.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06408610 nacompletednot on this mapstarted 2024, after this paper: background citation

Moderate Continuous Versus High Interval Intensity Training on Gut Dysbiosis and Glucagon Like Peptide Hormone in Irritable Bowel Syndrome

TypeinterventionalSponsorCairo UniversityRan2024 to 2025Enrolled66ConditionsIrritable Bowel Syndrome, Obesity, DysbiosisArmsmoderate intensity continuous training
3 · Its place in the literature

Who cites it

645 citing papers in PubMed, 7 syntheses or guidelines pooled it, 1,085 citations in OpenAlex.

  1. Lipopolysaccharide-mediated macrophage polarization, conserved pathogenesis, and implications for peripheral neuropathy: a systematic review.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. The Effects of a Prebiotic Formula PromotingInternational journal of medical sciences · 2026
    Trial
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review

585 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Arianna K DeGruttola*Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts; †Department of Immunology, Kurume University School of Medicine, Kurume, Fukuoka, Japan; and ‡Gastrointestinal Unit, Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Daren Low
Atsushi Mizoguchi
Emiko Mizoguchi
Kurume University · JPMassachusetts General Hospital · US

Funding

Inducible Regulatory B cells IBREGR01AI081807 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI REINECKER, HANS-CHRISTIAN · 2011 to 2015
$1.9M
Role of Mammalian Chitinases in Inflammatory Bowel DiseaseR01DK080070 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI MIZOGUCHI, EMIKO · 2009 to 2013
$1.6M
IL-22 pathway in IBDR01DK091247 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI REINECKER, HANS-CHRISTIAN · 2013 to 2016
$1.4M
NIAID NIH HHS AI81807NIAID NIH HHS R01 AI081807NIDDK NIH HHS DK91247NIDDK NIH HHS R01 DK080070NIDDK NIH HHS R01 DK091247NIDDK NIH HHS R01-DK80070
6 · The paper itself

Abstract

Inflammatory bowel disease (IBD) is an intestinal inflammatory condition that affects more than 2 million people in the United States. Although the etiology and pathogenesis of IBD are still largely unknown, dysregulated host/enteric microbial interactions are requisite for the development of IBD. So far, many researchers have tried to identify a precise relationship between IBD and an imbalance of the intestinal microbiota, termed "dysbiosis." Despite extensive efforts, it is still largely unknown about the interplay among microbes, their hosts, and their environments, and whether dysbiosis is a causal factor or an effect of IBD. Recently, deep-sequencing analyses of the microbiota in patients with IBD patients have been instrumental in characterizing the strong association between dysbiosis and IBD development, although it is still unable to identify specific-associated species level changes in most cases. Based on many recent reports, dysbiosis of the commensal microbiota is implicated in the pathogenesis of several diseases, including IBD, obesity, and allergic disorders, in both human and animal models. In this review article, the authors have focused on explaining the multiple types of dysbiosis, as well as dysbiosis-related diseases and potential treatments to apply this knowledge to understand a possible cause and potentially find therapeutic strategies for IBD as well as the other dysbiosis-related diseases.

Indexed as

Models, BiologicalAnimalsDysbiosisHumansInflammatory Bowel Diseases

Identifiers

PMID27070911
PMCPMC4838534
OpenAlexW2337372962

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.